Published in Medical Letter on the CDC and FDA, August 22nd, 2010
Net income from continuing operations for the first quarter was $9.6 million, or $0.19 of fully diluted earnings per share, 20% higher than the prior year's comparable period's net income of $8.0 million or $0.16 per fully diluted share.
Total revenues for the quarter ended June 30, 2010 were $73.4 million, 3% higher than the prior year comparable quarter's results of $71.0 million.
Operating income for the first fiscal quarter was $21.3 million, 15% higher than the prior year's comparable period results...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.